Yazar "Aslan M." seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Corrigendum to “European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)” (Redox Biol. (2017) 13 (94–162)(S2213231717303373)(10.1016/j.redox.2017.05.007))
    (Elsevier B.V., 2018) Egea J.; Fabregat I.; Frapart Y.M.; Ghezzi P.; Görlach A.; Kietzmann T.; Kubaichuk K.; Knaus U.G.; Lopez M.G.; Olaso-Gonzalez G.; Petry A.; Schulz R.; Vina J.; Winyard P.; Abbas K.; Ademowo O.S.; Afonso C.B.; Andreadou I.; Antelmann H.; Antunes F.; Aslan M.; Bachschmid M.M.; Barbosa R.M.; Belousov V.; Berndt C.; Bernlohr D.; Bertrán E.; Bindoli A.; Bottari S.P.; Brito P.M.; Carrara G.; Casas A.I.; Chatzi A.; Chondrogianni N.; Conrad M.; Cooke M.S.; Costa J.G.; Cuadrado A.; My-Chan Dang P.; De Smet B.; Debelec-Butuner B.; Dias I.H.K.; Dunn J.D.; Edson A.J.; El Assar M.; El-Benna J.; Ferdinandy P.; Fernandes A.S.; Fladmark K.E.; Förstermann U.; Giniatullin R.; Giricz Z.; Görbe A.; Griffiths H.; Hampl V.; Hanf A.; Herget J.; Hernansanz-Agustín P.; Hillion M.; Huang J.; Ilikay S.; Jansen-Dürr P.; Jaquet V.; Joles J.A.; Kalyanaraman B.; Kaminskyy D.; Karbaschi M.; Kleanthous M.; Klotz L.O.; Korac B.; Korkmaz K.S.; Koziel R.; Kracun D.; Krause K.H.; Kren V.; Krieg T.; Laranjinha J.; Lazou A.; Li H.; Martínez-Ruiz A.; Matsui R.; McBean G.J.; Meredith S.P.; Messens J.; Miguel V.; Mikhed Y.; Milisav I.; Milkovic L.; Miranda-Vizuete A.; Mojovic M.; Monsalve M.; Mouthuy P.A.; Mulvey J.; Münzel T.; Muzykantov V.; Nguyen I.T.N.; Oelze M.; Oliveira N.G.; Palmeira C.M.; Papaevgeniou N.; Pavicevic A.; Pedre B.; Peyrot F.; Phylactides M.; Pircalabioru G.G.; Pitt A.R.; Poulsen H.E.; Prieto I.; Rigobello M.P.; Robledinos-Antón N.; Rodríguez-Mañas L.; Rolo A.P.; Rousset F.; Ruskovska T.; Saraiva N.; Sasson S.; Schröder K.; Semen K.; Seredenina T.; Shakirzyanova A.; Smith G.L.; Soldati T.; Sousa B.C.; Spickett C.M.; Stancic A.; Stasia M.J.; Steinbrenner H.; Stepanic V.; Steven S.; Tokatlidis K.; Tuncay E.; Turan B.; Ursini F.; Vacek J.; Vajnerova O.; Valentová K.; Van Breusegem F.; Varisli L.; Veal E.A.; Yalçın A.S.; Yelisyeyeva O.; Zarkovic N.; Zatloukalová M.; Zielonka J.; Touyz R.M.; Papapetropoulos A.; Grune T.; Lamas S.; Schmidt H.H.H.W.; Di Lisa F.; Daiber A.
    The authors regret that they have to correct the acknowledgement of the above mentioned publication as follows: This article/publication is based upon work from COST Action BM1203 (EU-ROS), supported by COST (European Cooperation in Science and Technology) which is funded by the Horizon 2020 Framework Programme of the European Union. COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation. For further information see www.cost.eu. The authors would like to apologise for any inconvenience caused. © 2017 The Author(s)
  • Küçük Resim Yok
    Öğe
    Genetic Diversity and Antifungal Susceptibility of Candida parapsilosis Sensu Stricto Isolated from Bloodstream Infections in Turkish Patients
    (Springer Netherlands, 2018) Hilmioğlu-Polat S.; Sharifynia S.; Öz Y.; Aslan M.; Gündoğdu N.; Serin A.; Rafati H.; Mohammadi F.; Yeşim-Metin D.; Döğen A.; Ilkit M.; Seyedmousavi S.
    Candida parapsilosis sensu stricto is an emerging cause of hospital-acquired Candida infections, predominantly in southern Europe, South America, and Asia. We investigated the genetic diversity and antifungal susceptibility profile of 170 independent C. parapsilosis sensu stricto strains obtained from patients with candidemia who were treated at the Ege University Hospital in Izmir, Turkey, between 2006 and 2014. The identity of each strain was confirmed via PCR amplification and digestion of the secondary alcohol dehydrogenase-encoding gene. The 24-h geometric mean minimum inhibitory concentrations of the antifungal agents, in increasing order, were as follows: posaconazole, 0.10 µg/mL; voriconazole, 0.21 µg/mL; caspofungin, 0.38 µg/mL; amphotericin B, 0.61 µg/mL; anidulafungin, 0.68 µg/mL; and fluconazole, 2.95 µg/mL. Microsatellite genotyping of the isolates (using fluorescently labeled primers and a panel of four different short-nucleotide repeat fragments) identified 25, 17, 17, and 8 different allelic genotypes at the CP6, B5, CP4, and CP1 locus, respectively. Posaconazole, caspofungin, and amphotericin B showed the greatest in vitro activity of the tested systemic azole, echinocandin, and polyene agents, respectively, and the observed antifungal susceptibility of the isolates was shown to be independent of their isolation source. We obtained a combined discriminatory power of 0.99 with a total of 130 genotypes for 170 isolates tested. Finally, microsatellite profiling analysis confirmed the presence of identical genotype between separate isolates, supporting that effective surveillance and infection-prevention programs are essential to limit the impact of C. parapsilosis sensu stricto on hospitalized patients’ health. © 2018, Springer Science+Business Media B.V., part of Springer Nature.
  • Küçük Resim Yok
    Öğe
    Identification of hypoglycaemic compounds from berries of Juniperus oxycedrus subsp. oxycedrus through bioactivity guided isolation technique
    (2012) Orhan N.; Aslan M.; Pekcan M.; Orhan D.D.; Bedir E.; Ergun F.
    Ethnopharmacological relevance: Decoction of Juniperus oxycedrus subsp. oxycedrus L. (Cupressaceae) berries is used internally as tea and pounded fruits are consumed to lower blood glucose levels in Turkey. Aim of the study: To evaluate hypoglycaemic and antidiabetic activity of J. oxycedrus subsp. oxycedrus berries and to identify active compounds through bioactivity guided isolation technique. Material and methods: Hypoglycaemic effect of J. oxycedrus subsp. oxycedrus (Joso) berry extracts on oral administration was studied using in vivo models in normal, glucose-hyperglycaemic rats. Streptozotocin induced diabetic rats were used to examine antidiabetic activity of Joso extracts, subextracts, fractions, subfractions and shikimic acid (SA). Results: Through in vivo bioactivity-guided fractionation processes, shikimic acid, 4-O-ß-d-glucopyranosyl ferulic acid and oleuropeic acid-8-O-ß-d- glucopyranoside were isolated from the n-butanol subextract by silica gel and reverse phase column chromatography as the main active ingredient of the active subfraction. After 8 days administration of the major compound shikimic acid, blood glucose levels (24%), malondialdehyde levels in kidney tissues (63-64%) and liver enzymes (AST, ALT, ALP) of diabetic rats were decreased. Conclusion: Results indicated that Joso berry extract and its active constituents might be beneficial for diabetes and its complications. © 2011 Elsevier Ireland Ltd. All rights reserved.